I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Robert Alan Brodsky, M.D.
Director, Division of Hematology
Professor of Medicine
Expertise: Aplastic Anemia, Bone Marrow Failure, Hematologic Malignancies, Hematology, Medical Oncology, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria ...read more
Research Interests: high-dose cyclophosphamide, aplastic anemia, paroxysmal nocturnal hemoglobinuria
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is hematology. Through research, he and his colleagues have pioneered the use of high-dose cyclophosphamide therapy for the treatment of aplastic anemia and other autoimmune conditions.
Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Oncology Research and a member of the Johns Hopkins Kimmel Cancer Center.
He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997.
Dr. Brodsky's research interests include high-dose cyclophosphamide, aplastic anemia and paroxysmal nocturnal hemoglobinuria.
He has been recognized with numerous honors. In 2013, he received the Clinical Research Achievement Award from the Clinical Research Forum for second most important clinical research paper in medicine. He was named a Clinical Research Scholar of the Leukemia and Lymphoma Society of America in 2000 and a fellow of the American College of Physicians in 2004. He is a member of the American Society of Hematology and the International Society of Experimental Hematology.
- Director, Division of Hematology
- Program Director, T32 Training Program, Division of Hematology
- Johns Hopkins Family Professor of Oncology Research
- Professor of Medicine
- Professor of Oncology
- MD, Hahnemann University Hospital (1989)
- Vanderbilt University School of Medicine / Internal Medicine (1991)
- National Institutes of Health-Credentialing Services Section / Hematology (1994)
- Johns Hopkins University School of Medicine / Oncology (1997)
- American Board of Internal Medicine / Hematology (1996)
Research & Publications
Dr. Brodsky's major clinical research involves the study of aplastic anemia, paroxysmal nocturnal hemoglobinuria and other bone marrow failure disorders. His research shows that immunoablative doses of cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia. The reason high-dose cyclophosphamide is able to ablate the effector cells without destroying hematopoietic stem cells is that the earliest stem cells (but not lymphocytes) contain high levels of aldehyde dehydrogenase conferring resistance to the cytoxic properties of cyclophosphamide. Dr. Brodsky and his colleagues in neurology and rheumatology are applying this approach in other severe autoimmune disorders including, scleroderma, myasthenia gravis, multiple sclerosis and autoimmune hematologic disorders.
Dr. Brodsky's major laboratory interests relate to the study of normal and abnormal hematopoiesis. Specifically his lab studies PIG-A gene mutations in aplastic anemia. His group has developed a novel diagnostic assay for PNH based on the pore forming toxin (aeromonas hydrophila).
Clinical Trial Keywordsaplastic anemia, high-dose cyclophosphamide
Brodsky RA. Paroxysmal Nocturnal Hemoglobinuria. Blood. 2014 [in press]
DeZern AE, Uknis M, Yuan X, Mukhina GL, Varela J, Saye J, Pu J, Brodsky RA. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2014. pii: S0301-472X(14)00241-0. PMID: 25034232 [Epub ahead of print]
Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES. The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2014. pii: S1558-7673(14)00118-9. PMID: 24999166 [Epub ahead of print]
Smith C, Gore A, Yan W, Abalde-Atristain L, Li Z, He C, Wang Y, Brodsky RA, Zhang K, Cheng L, Ye Z. Whole-Genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-Based genome editing in human iPSCs. Cell Stem Cell 2014;15(1):12-3. PMID: 24996165.
Showel MM, Brodsky RA, Tsai HL, Briel KM, Kowalski J, Griffin CA, Jones RJ. Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy. Biol Blood Marrow Transplant 2014;20(8):1130-8. PMID: 24732780.
DeZern AE, Symons HJ, Resar LS, Borowitz MJ, Armanios MY, Brodsky RA. Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes. Eur J Haematol. 2014:92(6):467-70. PMID: 24612308.
Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P. Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry. Haematologica. 2014;99(5):922-9. PMID: 24488565; PMCID: PMC4008114.
Belet S, Fieremans N, Yuan X, Van Esch H, Verbeeck J, Ye Z, Cheng L, Brodsky BR, Hu H, Kalscheuer VM, Brodsky RA, Froyen G. Early Frameshift Mutation in PIGA Identified in a Large XLID Family Without Neonatal Lethality. Hum Mutat. 2014;35(3):350-5. PMID: 24357517.
Varela JC, Brodsky RA. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition. Expert Rev Clin Immunol. 2013;9(11):1113-24. PMID: 24168416.
Yuan X, Braunstein E, Ye Z, Liu C, Chen G, Zhou J, Cheng L, Brodsky RA. Generation of GPI anchor protein deficient blood celss from human induced pluripotent stem cells. Stem Cells Translational Medicine. 2013; 2(11):819-29. PMID: 24113066; PMCID: PMC3808197.
DeZern AE, Pu J, McDevitt MA, Jones RJ, Brodsky RA. Burst-Forming Unit-Erythroid Assays (BFU-E) To Distinguish Cellular Bone Marrow Failure Disorders. Exp Hematology. 2013;41(9):808-16. PMID: 23660070; PMCID: PMC3769493.
Peter Hillmen, Petra Muus, Alexander Röth, Modupe O. Elebute, Antonio M. Risitano, Hubert Schrezenmeier, Jeffrey Szer, Paul Browne, Jaroslaw P. Maciejewski, Jörg Schubert, Alvaro Urbano-Ispizua, Carlos de Castro, Gérard Socié, Robert A. Brodsky. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013; 162(1):62-73. PMID: 23617322; PMCID: PMC3744747.
DeZern AE, Styler MJ, Drachman D, Hummers L, Jones RJ, Brodsky RA. Repeated treatment for severe autoimmune diseases with high dose cyclophosphomide. American Journal of Blood Research. 2013;3(1):84-90. PMID: 23358715; PMCID: PMC3555191.
Kasamon YL, Brodsky RA, Borowitz MJ, Ambinder RF, et al. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma. 2013;54(3):483-90. PMID: 22835045.
Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285-9. PMID: 22955919; PMCID: PMC3507140
Pu JJ, Hu R, Mukhina GL, Carraway HE, McDevitt MA, Brodsky RA. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica. 2012;97(8):1225-33. PMID: 22315493; PMCID: PMC3409821.
Johnston JJ, Gropman AL, Sapp JC, Teer JK, Martin JM, Liu CF, Yuan X, Ye Z, Cheng L, Brodsky RA, Biesecker LG. The Phenotype of A Germline Mutation in PIGA: The Gene Somatically Mutated in Paroxysmal Nocturnal Hemoglobinuria. Am J Hum Genet. 2012;90(2):295-300. PMID: 22305531.
Harrison DM, Gladstone DE, Hammond E, Cheng J, Jones RJ, Brodsky RA, Kerr D, McArthur JC, Kaplin A. Treatment of relapsing-remitting multiple sclerosis with highdose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler. 2012; 18(2):202-9. PMID 21865410.
Gladstone DE, Bolanos-Meade J, Huff CA, Zahurak M, Flinn I, Borrello I, Luznik L, Fuchs E, Kasamon Y, Matsui W, Powell J, Levitsky H, Brodsky RA, Ambinder R, Jones RJ, Swinnen LJ. High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma. 2011; 52(11):2076-81. PMID: 21756035.
Pu JJ, Brodsky RA. Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. Clinical and Translational Science. 2011;4(3):219-24. PMID:21707954; PMCID:PMC3128433.
Activities & Honors
- Chairman's Invitational Honors Program, 1988
- Samuel Levit, M.D. Award - Outstanding Clinical and Humanitarianism in the care of Medical Patients, 1989
- James P. Fullin Memorial Award - Outstanding Clinical and Academic Performance in Hematology/Oncology, 1989
- Academic Honors: Oncology, 1989
- Academic Distinctions: Medicine, Neurology, 1989
- American Society of Hematology Travel Award, 1994
- 1st Prize, Johns Hopkins Oncology Center Fellow Research Day, 1996
- American Society of Hematology Travel Award, 1996
- Thomas E. Sandefur, Jr. Fellow in Stem Cell Research, 1997
- Junior Faculty Scholar, American Society of Hematology, 1998
- Leukemia and Lymphoma Society of America Scholar, 2000
- 2013 Clinical Research Forum: Clinical Research Achievement Award for 2nd most important clinical research paper in medicine; HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease, Blood, 2012
- American College of Physicians, 2004
- American Society of Hematology, 1994
- International Society of Experimental Hematology, 2001
Videos & Media
Johns Hopkins Medicine: Aplastic Anemia
A Remarkable Journey
Sickle Cell Breakthrough | Shauna's Story
Robert Brodsky and Half-match Bone Marrow Transplants in Sickle Cell Patients
Recent News Articles and Media Coverage
“Sickle Cell Transplants Could See Wider Use,” The New York Times, Nov. 12, 2012